Original ResearchA Pooled Analysis of Multicenter Cohort Studies of 123I-mIBG Imaging of Sympathetic Innervation for Assessment of Long-Term Prognosis in Heart Failure
Under an Elsevier user license
open archive
Key Words
cardiac sympathetic nerve function
heart failure
metaiodobenzylguanidine
pooled analysis
prognosis
Abbreviations and Acronyms
BNP
B-type natriuretic peptide
HF
heart failure
HMR
heart-to-mediastinum ratio
I
iodine
ICD
implantable cardioverter-defibrillator
LVEF
left ventricular ejection fraction
mIBG
metaiodobenzylguanidine
NE
norepinephrine
NRI
net reclassification improvement
NYHA
New York Heart Association
ROC
receiver-operating characteristic
VT
ventricular tachycardia
WR
washout rate
Cited by (0)
Dr. Travin has participated in a GE Healthcare research project. Dr. Jacobson is an employee and stockholder of GE Healthcare, which manufactures metaiodobenzylguanidine in the United States and Europe. Dr. Jacobson participated in this project as a scientist. Aside from Dr. Jacobson’s salary support, GE Healthcare provided no financial support for this study and was not involved in data analysis. 123Iodine-metaiodobenzylguanidine used in this study was commercially provided by Daiichi Radioisotope/Fujifilm RI Pharma, Tokyo, Japan. Other investigators are from academic and/or prefectural institutes or hospitals. All other authors have reported they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.